Upregulation of UBE2T levels has been disclosed to enhance gastric cancer development through RACK1 ubiquitination, and a novel powerful UBE2T inhibitor has been identified to suppress gastric cancer progression by blocking RACK1 ubiquitination after aberrant Wnt/β-catenin signaling (40). Here, RACK1 is linked to gastric cancer.